| Mr Kristian S Baker, LMFT | |
|
129 S State St Ste 250, Clearfield, UT 84015-1116 | |
| (801) 855-7999 | |
| (801) 855-7999 |
| Full Name | Mr Kristian S Baker |
|---|---|
| Gender | Male |
| Speciality | Marriage & Family Therapist |
| Location | 129 S State St Ste 250, Clearfield, Utah |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1003244609 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 106H00000X | Marriage & Family Therapist | 8541686-3902 (Utah) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Mr Kristian S Baker, LMFT 129 S State St Ste 250, Clearfield, UT 84015-1116 Ph: (801) 855-7999 | Mr Kristian S Baker, LMFT 129 S State St Ste 250, Clearfield, UT 84015-1116 Ph: (801) 855-7999 |
News Archive
A team of scientists led by Dr Simon Richardson at the University of Greenwich has got a step closer to one of the holy grails of drug delivery.
Avalere Health projects that of the 8.9 million people "determined eligible" for Medicaid starting last Oct. 1, the number of new enrollees under the health law is likely much smaller - between 2.4 million and 3.5 million. Other reports look at how health insurance could result in nearly half a million more Americans getting tested for HIV by 2017 - but how 60,000 people with the virus will be left uninsured in states not expanding Medicaid.
Haemonetics Corporation today reported second quarter fiscal 2014 net revenue of $235.8 million, up 8%, GAAP net income of $16.5 million and earnings per share of $0.32. Adjusted net income, exclusive of transformation, integration and deal amortization expenses detailed below, was $34.4 million, up 24%, and adjusted earnings per share were $0.66, up 24%. Excluding currency impact, net revenue was up 11% in the quarter.
YM BioSciences Inc., today announced that it has received positive opinions from the Committee for Orphan Medicinal Products of the European Commission to grant Orphan Medicinal Product Designation to its JAK1/JAK2 inhibitor, CYT387, for the treatment of primary myelofibrosis, post-polycythaemia vera myelofibrosis and post-essential thrombocythaemia myelofibrosis.
› Verified 5 days ago
Michael Sean Mccolley, AMFT Couples Therapy Medicare: Not Enrolled in Medicare Practice Location: 1246 S Legend Hills Dr Ste A7, Clearfield, UT 84015 Phone: 801-528-2855 |